SCHEMBL2801474

SCHEMBL2801474

O=C(O)c1ccc(Br)c(OCCC(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.41
POLB P06746 1/20 0.41
CASP6 P55212 1/20 0.41
TSHR P16473 2/20 0.40
PTPN11 Q06124 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39
CA7 P43166 1/20 0.39
TPMT P51580 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
TTR P02766 2/20 0.38
ALB P02768 1/20 0.38
ALDH1A1 P00352 2/20 0.37
HPGD P15428 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2802978 0.85 TSHR (0.42) MAPK1POLBCASP6TSHRCA12
SCHEMBL2802266 0.85 NOTUM (0.46) POLBCA12CA1CA2CA7
SCHEMBL9996991 0.83 POLB (0.43) MAPK1POLBCASP6TSHRPTPN11
SCHEMBL2802997 0.82 PTPN11 (0.44) POLBCASP6TSHRPTPN11CA12
SCHEMBL4910176 0.81 POLB (0.44) POLBCASP6TSHRPTPN11CA12
SCHEMBL8773610 0.80 KMT2A (0.54) POLBCASP6TSHRPTPN11CA12
SCHEMBL31500910 0.80 PLAU (0.47) MAPK1POLBCASP6TSHRPTPN11
SCHEMBL977445 0.79 PLA2G2D (0.42) POLBCASP6TSHRPTPN11CA12
SCHEMBL2802209 0.79 PLA2G2D (0.45) POLBCASP6TSHRPTPN11CA12
SCHEMBL2499117 0.79 TP53 (0.58) TSHRPTPN11ALDH1A1HPGDRARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy PTGER1, SULT2A1, SULT1E1 MAPK1 2052/4885POLB 2414/4885CASP6 3764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.